Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2013

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2013

Jul 2013 Global Markets Direct Lymphoma100 Pages Price :
$ 2000

Global Markets Directs, Peripheral T-Cell Lymphomas (PTCL) Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL). Peripheral T-Cell Lymphomas (PTCL) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Peripheral T-Cell Lymphomas (PTCL).
  • A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peripheral T-Cell Lymphomas (PTCL) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) 8
Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Development by Companies 10
Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Peripheral T-Cell Lymphomas (PTCL) Therapeutics – Products under Development by Companies 16
Peripheral T-Cell Lymphomas (PTCL) Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Peripheral T-Cell Lymphomas (PTCL) Therapeutics Development 18
Kyowa Hakko Kirin Co., Ltd. 18
ZIOPHARM Oncology, Inc. 19
Millennium Pharmaceuticals, Inc. 20
Eisai Co., Ltd. 21
Celgene Corporation 22
TopoTarget A/S 23
Mundipharma International Limited 24
Spectrum Pharmaceuticals, Inc. 25
Chipscreen Biosciences Ltd 26
Peripheral T-Cell Lymphomas (PTCL) – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
alisertib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HBI-8000 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
belinostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
mogamulizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
forodesine hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
darinaparsin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
darinaparsin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pralatrexate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pralatrexate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
lenalidomide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
romidepsin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
romidepsin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
denileukin diftitox - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
alefacept - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Peripheral T-Cell Lymphomas (PTCL) Therapeutics – Drug Profile Updates 64
Peripheral T-Cell Lymphomas (PTCL) Therapeutics – Discontinued Products 89
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Dormant Products 90
Peripheral T-Cell Lymphomas (PTCL) – Product Development Milestones 91
Featured News & Press Releases 91
Jun 03, 2013: Spectrum Pharma Presents Positive Data From BELIEF Trial At 2013 ASCO Annual Meeting 91
Jun 03, 2013: Topotarget Presents Positive Data From BELIEF Trial Of Belinostat In Patients With Peripheral T-cell Lymphoma At 2013 ASCO Annual Meeting 92
Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China 92
Mar 05, 2013: TopoTarget\'s Belinostat Exceeds Primary Endpoint In Pivotal Trial For Patients With Peripheral T-cell Lymphoma 93
Jan 24, 2013: Topotarget\'s Belinostat Demonstrates Favorable Safety Profile In Phase II Peripheral T-cell Lymphoma Study 94
Jan 08, 2013: TG Therapeutics Initiates First-in-human Phase I Clinical Trial For TGR-1202 In Patients With Hematologic Malignancies 95
Dec 21, 2012: Spectrum Pharma\'s Belinostat Surpasses Primary Endpoint In Registrational Phase II Trial 95
Dec 11, 2012: Kyowa Hakko Kirin Announces Presentation Of Phase II Clinical Trial Results Of Mogamulizumab At ASH Annual Meeting 96
Dec 07, 2012: Spectrum Pharma Announces Presentation Of Abstracts On Folotyn At 54th Annual Meeting of ASH 97
Nov 15, 2012: Celgene\'s Istodax Receives CHMP Negative Opinion For Treatment Of Peripheral T-cell Lymphoma 98

Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Table


Number of Products Under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2013 8
Products under Development for Peripheral T-Cell Lymphomas (PTCL) Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Kyowa Hakko Kirin Co., Ltd., H2 2013 18
ZIOPHARM Oncology, Inc., H2 2013 19
Millennium Pharmaceuticals, Inc., H2 2013 20
Eisai Co., Ltd., H2 2013 21
Celgene Corporation, H2 2013 22
TopoTarget A/S, H2 2013 23
Mundipharma International Limited, H2 2013 24
Spectrum Pharmaceuticals, Inc., H2 2013 25
Chipscreen Biosciences Ltd, H2 2013 26
Assessment by Monotherapy Products, H2 2013 27
Assessment by Stage and Route of Administration, H2 2013 29
Assessment by Stage and Molecule Type, H2 2013 31
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Drug Profile Updates 64
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Discontinued Products 89
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Dormant Products 90

List of Chart


Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2013 8
Products under Development for Peripheral T-Cell Lymphomas (PTCL) Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Late Stage Products, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Early Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 27
Assessment by Route of Administration, H2 2013 28
Assessment by Stage and Route of Administration, H2 2013 29
Assessment by Molecule Type, H2 2013 30
Assessment by Stage and Molecule Type, H2 2013 31

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top